[{"id":"ce51dd71-f581-4b05-8883-08013dc38521","acronym":"","url":"https://clinicaltrials.gov/study/NCT05107037","created_at":"2021-11-04T16:57:13.962Z","updated_at":"2024-07-02T16:36:21.312Z","phase":"Phase 1","brief_title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQ-B3234 in Patients With Type I Neurofibromatosis","source_id_and_acronym":"NCT05107037","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TQ-B3234"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2021-11-04"}]